amg 386 Latest Research Papers

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

Kidney Cancer ◽

10.3233/kca-180041 ◽

2019 ◽

Vol 3 (1) ◽

pp. 51-61 ◽

Cited By ~ 1

Author(s):

Thomas J Semrad ◽

Susan Groshen ◽

Chunqiao Luo ◽

Sumanta Pal ◽

Ulka Vaishampayan ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Vascular Endothelial ◽

Phase 2 ◽

Amg 386 ◽

Phase 2 Study ◽

Factor Therapy ◽

Growth Factor Therapy ◽

Endothelial Growth Factor ◽

Randomized Phase 2

Download Full-text

Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer

10.1158/1538-7445.am2018-2611 ◽

2018 ◽

Author(s):

Denise M. Wolf ◽

Christina Yau ◽

Lamorna Brown-Swigart ◽

Gillian Hirst ◽

I-SPY TRIAL Investigators ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Stage Ii ◽

Predictors Of Response ◽

Amg 386 ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Risk Breast Cancer

Download Full-text

Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e16121 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e16121-e16121 ◽

Cited By ~ 1

Author(s):

Thomas John Semrad ◽

Susan G. Groshen ◽

Sumanta K. Pal ◽

Ulka N. Vaishampayan ◽

Monika Joshi ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renal Cell ◽

Vascular Endothelial ◽

Phase 2 ◽

Amg 386 ◽

Phase 2 Study ◽

Endothelial Growth Factor ◽

Randomized Phase 2

Download Full-text

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2016.1161027 ◽

2016 ◽

Vol 17 (6) ◽

pp. 853-860 ◽

Cited By ~ 11

Author(s):

Khalid Al Wadi ◽

Prafull Ghatage

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Amg 386

Download Full-text

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

Neuro-Oncology ◽

10.1093/neuonc/nov206.22 ◽

2015 ◽

Vol 17 (suppl 5) ◽

pp. v6.2-v6 ◽

Cited By ~ 1

Author(s):

Eudocia Q. Lee ◽

Peixin Zhang ◽

Patrick Y. Wen ◽

Elizabeth R. Gerstner ◽

David A. Reardon ◽

...

Keyword(s):

Phase Ii ◽

Recurrent Glioblastoma ◽

Controlled Study ◽

Amg 386 ◽

Double Blinded

Download Full-text

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.07.006 ◽

2015 ◽

Vol 138 (3) ◽

pp. 513-518 ◽

Cited By ~ 24

Author(s):

Kathleen N. Moore ◽

Michael W. Sill ◽

Meaghan E. Tenney ◽

Christopher J. Darus ◽

David Griffin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Recurrent Carcinoma ◽

Amg 386 ◽

Group Trial ◽

Angiopoietin 1

Download Full-text

Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer

Current Angiogenesis ◽

10.2174/2211552804666150331222508 ◽

2015 ◽

Vol 3 (4) ◽

pp. 193-202

Author(s):

Al Wadi Khalid ◽

Ghatage Prafull

Keyword(s):

Ovarian Cancer ◽

Amg 386

Download Full-text

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

The Breast ◽

10.1016/j.breast.2014.11.003 ◽

2015 ◽

Vol 24 (3) ◽

pp. 182-190 ◽

Cited By ~ 32

Author(s):

Véronique Diéras ◽

Hans Wildiers ◽

Jacek Jassem ◽

Luc Y. Dirix ◽

Jean-Paul Guastalla ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Amg 386 ◽

Locally Recurrent

Download Full-text

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.02.001 ◽

2015 ◽

Vol 94 (3) ◽

pp. 302-310 ◽

Cited By ~ 10

Author(s):

Claudia Marchetti ◽

Maria Luisa Gasparri ◽

Ilary Ruscito ◽

Innocenza Palaia ◽

Giorgia Perniola ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Treatment ◽

Amg 386

Download Full-text

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-015-0236-4 ◽

2015 ◽

Vol 33 (3) ◽

pp. 691-699 ◽

Cited By ~ 7

Author(s):

Jennifer R. Diamond ◽

Benjamin Wu ◽

Neeraj Agarwal ◽

Daniel W. Bowles ◽

Elaine T. Lam ◽

...

Keyword(s):

Drug Interaction ◽

Solid Tumors ◽

Advanced Solid Tumors ◽

Interaction Study ◽

Drug Interaction Study ◽

Amg 386 ◽

Drug Drug Interaction ◽

Angiopoietin 2 ◽

Pharmacokinetic Drug ◽

Angiopoietin 1

Download Full-text

amg 386
Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer

Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

Export Citation Format

amg 386Recently Published Documents

TOTAL DOCUMENTS

H-INDEX

Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048

Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer

Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA

A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial

Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)

Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

amg 386
Recently Published Documents